Summary

Sickle Cell Disease Treatment Market – Scope of Report
TMR’s report on the global sickle cell disease treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global sickle cell disease treatment market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global sickle cell disease treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the sickle cell disease treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global sickle cell disease treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global sickle cell disease treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global sickle cell disease treatment market.

The report delves into the competitive landscape of the global sickle cell disease treatment market. Key players operating in the global sickle cell disease treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global sickle cell disease treatment market profiled in this report.

Key Questions Answered in Global sickle cell disease treatment Market Report
• What is the sales/revenue generated by sickle cell disease treatment across all regions during the forecast period?
• What are the opportunities in the global sickle cell disease treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Sickle Cell Disease Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global sickle cell disease treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global sickle cell disease treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global sickle cell disease treatment market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sickle Cell Disease Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Sickle Cell Disease Treatment Market Analysis and Forecast, 2020-2034
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Key Industry Events
5.2. PEST Analysis
5.3. Pipeline Analysis
5.4. Regulatory Scenario by Key Countries/Regions
5.5. PORTER’s Five Forces Analysis
5.6. Reimbursement Scenario by Key Countries
5.7. Pricing Analysis
5.8. Product/Brand Analysis
5.9. Epidemiology of Sickle Cell Disease
5.10. Technological Advancements
5.11. Supply Chain Analysis
5.12. Unmet Needs of the Market
6. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Antimetabolites
6.3.2. Amino Acids
6.3.3. NSAIDs
6.3.4. Monoclonal Antibodies
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Type, 2020-2034
7.3.1. Hemoglobin SS (HbSS)
7.3.2. Hemoglobin SC (HbSC)
7.3.3. Hemoglobin (HbS) beta thalassemia
7.4. Market Attractiveness Analysis, by Disease Type
8. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Age-Group
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Age-Group, 2020-2034
8.3.1. Children
8.3.2. Adults
8.4. Market Attractiveness Analysis, by Age-Group
9. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Route of Administration
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Route of Administration, 2020-2034
9.3.1. Oral
9.3.2. Parenteral
9.4. Market Attractiveness Analysis, by Route of Administration
10. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2020-2034
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Sickle Cell Disease Treatment Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2020-2034
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Sickle Cell Disease Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2020-2034
12.2.1. Antimetabolites
12.2.2. Amino Acids
12.2.3. NSAIDs
12.2.4. Monoclonal Antibodies
12.2.5. Others
12.3. Market Value Forecast, by Disease Type, 2020-2034
12.3.1. Hemoglobin SS (HbSS)
12.3.2. Hemoglobin SC (HbSC)
12.3.3. Hemoglobin (HbS) beta thalassemia
12.4. Market Value Forecast, by Age-Group, 2020-2034
12.4.1. Children
12.4.2. Adults
12.5. Market Value Forecast, by Route of Administration, 2020-2034
12.5.1. Oral
12.5.2. Parenteral
12.6. Market Value Forecast, by Distribution Channel, 2020-2034
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Value Forecast, by Country, 2020-2034
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Drug Class
12.8.2. By Disease Type
12.8.3. By Age-Group
12.8.4. By Route of Administration
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Sickle Cell Disease Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2020-2034
13.2.1. Antimetabolites
13.2.2. Amino Acids
13.2.3. NSAIDs
13.2.4. Monoclonal Antibodies
13.2.5. Others
13.3. Market Value Forecast, by Disease Type, 2020-2034
13.3.1. Hemoglobin SS (HbSS)
13.3.2. Hemoglobin SC (HbSC)
13.3.3. Hemoglobin (HbS) beta thalassemia
13.4. Market Value Forecast, by Age-Group, 2020-2034
13.4.1. Children
13.4.2. Adults
13.5. Market Value Forecast, by Route of Administration, 2020-2034
13.5.1. Oral
13.5.2. Parenteral
13.6. Market Value Forecast, by Distribution Channel, 2020-2034
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Value Forecast, by Country/Sub-region, 2020-2034
13.7.1. Germany
13.7.2. UK
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Drug Class
13.8.2. By Disease Type
13.8.3. By Age-Group
13.8.4. By Route of Administration
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Sickle Cell Disease Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2020-2034
14.2.1. Antimetabolites
14.2.2. Amino Acids
14.2.3. NSAIDs
14.2.4. Monoclonal Antibodies
14.2.5. Others
14.3. Market Value Forecast, by Disease Type, 2020-2034
14.3.1. Hemoglobin SS (HbSS)
14.3.2. Hemoglobin SC (HbSC)
14.3.3. Hemoglobin (HbS) beta thalassemia
14.4. Market Value Forecast, by Age-Group, 2020-2034
14.4.1. Children
14.4.2. Adults
14.5. Market Value Forecast, by Route of Administration, 2020-2034
14.5.1. Oral
14.5.2. Parenteral
14.6. Market Value Forecast, by Distribution Channel, 2020-2034
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Value Forecast, by Country/Sub-region, 2020-2034
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Drug Class
14.8.2. By Disease Type
14.8.3. By Age-Group
14.8.4. By Route of Administration
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Sickle Cell Disease Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2020-2034
15.2.1. Antimetabolites
15.2.2. Amino Acids
15.2.3. NSAIDs
15.2.4. Monoclonal Antibodies
15.2.5. Others
15.3. Market Value Forecast, by Disease Type, 2020-2034
15.3.1. Hemoglobin SS (HbSS)
15.3.2. Hemoglobin SC (HbSC)
15.3.3. Hemoglobin (HbS) beta thalassemia
15.4. Market Value Forecast, by Age-Group, 2020-2034
15.4.1. Children
15.4.2. Adults
15.5. Market Value Forecast, by Route of Administration, 2020-2034
15.5.1. Oral
15.5.2. Parenteral
15.6. Market Value Forecast, by Distribution Channel, 2020-2034
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.7. Market Value Forecast, by Country/Sub-region, 2020-2034
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Drug Class
15.8.2. By Disease Type
15.8.3. By Age-Group
15.8.4. By Route of Administration
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Sickle Cell Disease Treatment Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Drug Class, 2020-2034
16.2.1. Antimetabolites
16.2.2. Amino Acids
16.2.3. NSAIDs
16.2.4. Monoclonal Antibodies
16.2.5. Others
16.3. Market Value Forecast, by Disease Type, 2020-2034
16.3.1. Hemoglobin SS (HbSS)
16.3.2. Hemoglobin SC (HbSC)
16.3.3. Hemoglobin (HbS) beta thalassemia
16.4. Market Value Forecast, by Age-Group, 2020-2034
16.4.1. Children
16.4.2. Adults
16.5. Market Value Forecast, by Route of Administration, 2020-2034
16.5.1. Oral
16.5.2. Parenteral
16.6. Market Value Forecast, by Distribution Channel, 2020-2034
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.7. Market Value Forecast, by Country/Sub-region, 2020-2034
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Drug Class
16.8.2. By Disease Type
16.8.3. By Age-Group
16.8.4. By Route of Administration
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis, by Company (2023)
17.3. Company Profiles
17.3.1. Bristol-Myers Squibb Company
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. Novartis AG
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.5. Recent Developments
17.3.3. Emmaus Medical, Inc.
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. Bluebird bio Inc.
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. Pfizer Inc.
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. CRISPR Therapeutics
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. F. Hoffmann-La Roche AG
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. Vertex Pharmaceuticals Incorporated
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
17.3.9. Agios Pharmaceuticals, Inc.
17.3.9.1. Company Overview
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Business Strategies
17.3.9.5. Recent Developments
17.3.10. GlycoMimetics
17.3.10.1. Company Overview
17.3.10.2. Financial Overview
17.3.10.3. Product Portfolio
17.3.10.4. Business Strategies
17.3.10.5. Recent Developments
17.3.11. Graphite Bio, Inc.
17.3.11.1. Company Overview
17.3.11.2. Financial Overview
17.3.11.3. Product Portfolio
17.3.11.4. Business Strategies
17.3.11.5. Recent Developments
17.3.12. Mylan N.V.
17.3.12.1. Company Overview
17.3.12.2. Financial Overview
17.3.12.3. Product Portfolio
17.3.12.4. Business Strategies
17.3.12.5. Recent Developments
17.3.13. Teva Pharmaceutical Industries Ltd.
17.3.13.1. Company Overview
17.3.13.2. Financial Overview
17.3.13.3. Product Portfolio
17.3.13.4. Business Strategies
17.3.13.5. Recent Developments
17.3.14. AstraZeneca
17.3.14.1. Company Overview
17.3.14.2. Financial Overview
17.3.14.3. Product Portfolio
17.3.14.4. Business Strategies
17.3.14.5. Recent Developments
17.3.15. Hikma Pharmaceuticals PLC
17.3.15.1. Company Overview
17.3.15.2. Financial Overview
17.3.15.3. Product Portfolio
17.3.15.4. Business Strategies
17.3.15.5. Recent Developments
17.3.16. Addmedica
17.3.16.1. Company Overview
17.3.16.2. Financial Overview
17.3.16.3. Product Portfolio
17.3.16.4. Business Strategies
17.3.16.5. Recent Developments